• 대한약학회:학술대회논문집
• /
• 대한약학회 2001년도 Proceedings of International Convention of the Pharmaceutical Society of Korea
• /
• pp.264.3-265
• /
• 2001

• IMMUNE NETWORK
• /
• 제2권2호
• /
• pp.115-124
• /
• 2002

Background: The chemical characteristics of the exo-secretion from Phellinus linteus (referred to as exo-secretion) including the compositions of amino acids and monosaccharides were investigated. In addition, cytotoxicity of the exo-secretion on 5 tumor cell lines derived from human cancers and its antitumor activity against ascitic sarcoma-180 cells were examined. Methods: The antitumor activity of exo-secretion from Phellinus linteus was determined by measuring parameters including tumor weight, life span of mice, chemotatic activity of leukocytes, counts of immune cells, and activity of cytokines. Results: The exo-secretion from Phellinus linteus showed no direct cytotoxicity to the five tumor cell lines tested, but it had a strong antitumor activity against sarcoma-180 cells in ICR mice as measured by tumor weight and life span of mice. The exo-secretion stimulated the chemotaxis of leukocytes and production of immune cells and cytokines. Conclusion: These results suggest that the exo-secretion from Phellinus linteus do not act as a direct cytotoxic substance to cancer cells but as an immunomodulator.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제21권1호
• /
• pp.1-11
• /
• 2018

The emergence of mucosal healing as a treatment goal that could modify the natural course of Crohn's disease and the accumulating evidence showing that biologics are most effective in achieving mucosal healing, along with the success of early treatment regimens for rheumatoid arthritis, have led to the identification of early Crohn's disease and development of the concept of catching the therapeutic window during the early disease course. Thus, an increasing number of pediatric gastroenterologists are adopting an early biologic treatment strategy with or without an immunomodulator. Although early biologic treatment is effective, cost and overtreatment are issues that limit its early use. Currently, there are insufficient data on who will benefit most from early biologics, as well as on who will not need early or even any biologics. For now, top-down biologics should be considered for patients with currently known high-risk factors of poor outcomes. For other patients, close, objective monitoring and accelerating the step-up process by means of a treat-to-target approach seems the best way to catch the therapeutic window in early pediatric Crohn's disease. The individual benefits of immunomodulator addition during early biologic treatment should be weighed against its risks and decision on early combination treatment should be made after comprehensive discussion with each patient and guardian.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제21권4호
• /
• pp.329-335
• /
• 2018

Loss of response to anti-tumor necrosis factor (anti-TNF) agents in the treatment of inflammatory bowel disease (IBD) is a major consideration to maintain sustained response. Reversal of immunogenicity can re-establish response and increase the durability of these agents. Strategies to reverse immunogenicity include dose-intensification and/or the addition of an immunomodulator. However, there is a relative paucity of data on the efficacy of such interventions in pediatric IBD patients. Available reports have not strictly utilized homogenous mobility shift assay, which reports on anti-drug antibodies even in the presence of detectable drug, whereas prior studies have been confounded by the use of drug sensitive assays. We report four pediatric inflammatory bowel disease patients with successful reversal of immunogenicity on an anti-TNF agent using dose intensification and/or addition of an immunomodulator.

• Archives of Pharmacal Research
• /
• 제28권8호
• /
• pp.892-896
• /
• 2005

In order to isolate substances that inhibit the hemolytic activity of human serum against eryth-rocytes, we have evaluated whole plants of the Orostachys japonicus species with regard to its anti-complement activity, and have identified its active principles following activity-guided isolation. A methanol extract of the O. japonicus, as well as its n-hexane soluble fraction, exhibited significant anti-complement activity on the complement system, which was expressed as total hemolytic activity. A bioassay-guided chromatographic separation of the constituents resulted in the isolation of three known compounds 1-3 from the active n-hexane fraction. The structure of these compounds were analyzed, and they were identified as hydroxyhopanone (1), $\beta-sitosteryl-3-O-\beta-D-glucopyranosyl-6'-O-palmitate$ (2), and $\beta-sitosteryl-3-O-\beta-D-glucopyranoside$ (3), respectively. Of these compounds, compound 2 exhibited potent anti-complement activity $(IC_{50}=1.0\pm0.1{\mu}M)$ on the classical pathway of the complement, as compared to tiliroside $(IC_{50}=76.5\pm1.1{\mu}M)$, which was used as a positive control. However, compounds 1 and 3 exhibited no activity in this system.

• Archives of Pharmacal Research
• /
• 제25권4호
• /
• pp.493-499
• /
• 2002

We investigated the antitumor activity of oregonin, a diarylheptanoid derivative purified from Alnus hirsuta Turcz, Betulaceae. Oregonin is a potential novel immunomodulator, which augments the activation of natural killer (NK) cells, and thereby leads to a powerful antitumor activity. To evaluate the cytotoxicity of oregonin against tumor cells, we examined the effectiveness of NK cells and determined that oregonin could increase NK cell cytotoxicity. This was confirmed by MTT assay. In addition, the survival time of C57BL/6 mice were measured by inoculating 816-F10 melanoma cells to mice via intra muscular (i.m.) injection. Oregonin treatment after 10 hours of inoculation at 10 mg/kg dosage showed a significant extension of survival time by up to 51.32%, when compared to the control group. Moreover, oregonin significantly reduced the incidence of pulmonary metastasis, which may be developed from 816-F10 melanoma cells. These findings suggest that oregon in may be classified as a new and novel immunomodulator due to its potential antitumor activity.

• Journal of Animal Science and Technology
• /
• 제53권5호
• /
• pp.409-418
• /
• 2011

복합생균제의 급여가 육계의 생산성, 도체특성, 분중 $NH_3$ 가스 생성량 및 장내 병원성 미생물 억제효과에 미치는 영향을 조사하기 위하여 토종 닭 육계 병아리 120수를 이용하여 9주간 시험을 실시하였다. 실험은 5처리 3반복의 완전임의 배치법으로 설계 하였으며, 처리 당 24수씩 배치하였다. 처리내용은 C (대조구로서 기초사료만 급여), T1 (기초사료에 항생제 첨가), T2 (기초사료에 생균제제 bio-Max$^{(R)}$ 첨가), T3 (기초사료에 생균제제 bio-${\alpha}$-Gold$^{(R)}$ 첨가), T4 (기초사료에 bio-MAX$^{(R)}$와 면역증강제인 ${\beta}$-glucan, 유기산의 추가 첨가)로 구분하였으며, 병아리들은 2주간의 적응기간을 거친 후 2~6주령은 육계전기사료, 6~9주령은 육계후기사료를 급여 하였다. 총 증체량은 항생제가 첨가된 T1에서 가장 높았으며(p<0.05), 대조구와 생균제 급여구 간에는 차이가 없었다. 사료 섭취량은 2~9주령에서는 T1과 T2에서 유의적으로 증가 하였다(p<0.05). 결과적으로 사료요구율은 대조구와 항생제 첨가구 그리고 T4에서 다른 처리구보다 낮게 나타났다(p<0.05). 처리구 별 생체중과 도체율은 T3와 T4에서 다른 처리구보다 높게 나타났으며, 가식 내장 무게는 간과 심장에서 T4가 유의하게 높게 나타났다(p<0.05). 계분 중의 $NH_3$ 가스 발생량은 6일에 최고치에 달했으며 9일 이후 감소하였다. 복합 생균제 제품급여 시 암모니아 가스 발생량에 대한 영향은 항생제 첨가 급여구에 비하여 낮게 나타났다. 생균제 첨가 급여 시 맹장 내 salmonella 수는 T4에서 현저히 감소하였고, 회장 내에서는 T2와 T4에서 감소하였다. 맹장 내 E. coli 수는 T4에서 현저히 감소하였고, 회장 내에서는 T1, T2와 T4에서 유의적으로 감소하였다(p<0.05). 복합 생균제 제품은 장내 병원성 미생물 수를 감소시켰으며, 특히 ${\alpha}$-Max$^{(R)}$ 제품에 면역증강제가 첨가된 복합 생균제의 효과가 다른 처리구보다 높았다. 따라서 복합생균제에 면역증강제의 혼합급여형태는 장내 병원성 미생물 억제측면에서 항생제를 대체할 수 있는 가능성이 높을 것으로 사료된다.

• 한국버섯학회지
• /
• 제6권1호
• /
• pp.1-12
• /
• 2008

Mushroom is well known for a safe food for a long time and, what is more, has a lot of useful characteristics related on the pharmacological activities. It is expected to be one of the most important functional food due to its diverse bioactive compounds. Especially, medical potentiality on immunomodulator and antitumor continues to be focused. Recent research trend and commercialization of functional healthy food using mushroom and its bioactive compounds will be herein introduced. Industrialization of mushroom functional substances will be also discussed.

• 한국미생물학회:학술대회논문집
• /
• 한국미생물학회 2007년도 International Meeting of the Microbiological Society of Korea
• /
• pp.140-140
• /
• 2007

• 한국생명과학회:학술대회논문집
• /
• 한국생명과학회 2006년도 제47회 학술심포지움 및 추계국제학술대회
• /
• pp.60.2-60.2
• /
• 2006